A survey on the use of anti-cancer CPMs among 51,382 insured cancer patients demonstrates that CKI is the second frequently used anti-cancer CPMs and is also the CPM with the highest use rate in 17 cancers; moreover, CKI is also the second commonly used anti-cancer CPMs in breast cancer (20). This evidence concerns the gene CHKA and cancer.